ReviewNature reviews. Drug discovery2009
Can literature analysis identify innovation drivers in drug discovery?
Review in Nature reviews. Drug discovery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Temporal trends in evidence supporting novel drug target discovery.Nature communications · 2025Article
- ARCH: Large-scale knowledge graph via aggregated narrative codified health records analysis.Journal of biomedical informatics · 2025Article
- Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections.Nature reviews. Drug discovery · 2023Review
- Global Research Status of Multiple Organ Dysfunction Syndrome During 2001-2021: A 20-Year Bibliometric Analysis.Frontiers in medicine · 2022Article
- The global research status and trends of the application of endoscopic ultrasonography in pancreatic tumors over the last decades: A bibliometric study.Frontiers in oncology · 2022Article
- When Cyclodextrins Met Data Science: Unveiling Their Pharmaceutical Applications through Network Science and Text-Mining.Pharmaceutics · 2021Article
- Measuring the Interactions Between Health Demand, Informatics Supply, and Technological Applications in Digital Medical Innovation for China: Content Mapping and Analysis.JMIR medical informatics · 2021Article
- US FDA Drug Approvals are Persistent and Polycyclic: Insights into Economic Cycles, Innovation Dynamics, and National Policy.Therapeutic innovation & regulatory science · 2021Article
- Article
- Polydatin Ameliorates Osteoporosis via Suppression of the Mitogen-Activated Protein Kinase Signaling Pathway.Frontiers in cell and developmental biology · 2021Article
- Adoption of the Citation Typing Ontology by the Journal of Cheminformatics.Journal of cheminformatics · 2020Article
- QSAR without borders.Chemical Society reviews · 2020Review
- Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives.Health research policy and systems · 2020Article
- The Reporting Items for Patent Landscapes statement.Nature biotechnology · 2018Article
- Unexplored therapeutic opportunities in the human genome.Nature reviews. Drug discovery · 2018Review
- When Neuroscience Meets Pharmacology: A Neuropharmacology Literature Analysis.Frontiers in neuroscience · 2018Article
- Retrofitting Concept Vector Representations of Medical Concepts to Improve Estimates of Semantic Similarity and Relatedness.Studies in health technology and informatics · 2017Article
- Modeling timelines for translational science in cancer; the impact of technological maturation.PloS one · 2017Article
- Biomechanisms of Comorbidity: Reviewing Integrative Analyses of Multi-omics Datasets and Electronic Health Records.Yearbook of medical informatics · 2016Review
- Tackling the "so what" problem in scientific research: a systems-based approach to resource and publication tracking.Academic medicine : journal of the Association of American Medical Colleges · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery must be guided not only by medical need and commercial potential, but also by the areas in which new science is creating therapeutic opportunities, such as target identification and the understanding of disease mechanisms. To systematically identify such areas of high scientific activity, we use bibliometrics and related data-mining methods to analyse over half a terabyte of data, including PubMed abstracts, literature citation data and patent filings. These analyses reveal trends in scientific activity related to disease studied at varying levels, down to individual genes and pathways, and provide methods to monitor areas in which scientific advances are likely to create new therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.